Abstract
The term Parkinson’s disease has been changed in ‘Parkinson's diseases’ to describe different clinical entities observed in several studies investigating the existence of PD subtypes. PD patients could be grouped based on clinical features. By considering only motor symptoms, we can classically distinguish two groups: “ the tremorigen-form” and “akinetic- rigidity-form” where resting tremor and akinesia/bradikynesia and rigidity are the most motor predominant symptoms, respectively. Non-motor symptoms (NMSs) are practically always present during the course of the disease and some of them (constipation, depressive status, hyposmia and anxiety) could even exist before the onset of classical motor symptoms. Many other NMSs and in particular hallucinations, cognitive impairment, sleep disorders and difficulty in swallowing strongly affect the advanced stage of disease, and represent a real therapeutic challenge when these symptoms are simultaneously present with different severity. If not adequately treated, they can increase the risk of hospitalization and admissions in nursing home, and profoundly and negatively influence the quality of life and participation in social activity of these patients. PD subtypes according to the combination of motor and non-motor symptoms have been recently proposed. This classification derives from cluster analysis which permits to identify statistically distinct subtypes of Parkinsonian patients according to the relevance of both motor and non-motor symptoms. In this point of view, we propose a schematic therapeutic approach of motor and non-motor symptoms in Parkinson’s disease according to cluster symptoms presentation (motor and non-motor symptoms) and using medications that act on multiple domains of PD symptoms.
Keywords: Cluster symptoms, motor symptoms, non-motor symptoms, Parkinson’s disease, subtypes, treatment.
Current Drug Targets
Title:Treatment of the Motor and Non-Motor Symptoms in Parkinson's Disease According to Cluster Symptoms Presentation
Volume: 15 Issue: 10
Author(s): Fulvio Lauretani, Antonio Saginario, Gian Paolo Ceda, Laura Galuppo, Livia Ruffini, Anna Nardelli and Marcello Maggio
Affiliation:
Keywords: Cluster symptoms, motor symptoms, non-motor symptoms, Parkinson’s disease, subtypes, treatment.
Abstract: The term Parkinson’s disease has been changed in ‘Parkinson's diseases’ to describe different clinical entities observed in several studies investigating the existence of PD subtypes. PD patients could be grouped based on clinical features. By considering only motor symptoms, we can classically distinguish two groups: “ the tremorigen-form” and “akinetic- rigidity-form” where resting tremor and akinesia/bradikynesia and rigidity are the most motor predominant symptoms, respectively. Non-motor symptoms (NMSs) are practically always present during the course of the disease and some of them (constipation, depressive status, hyposmia and anxiety) could even exist before the onset of classical motor symptoms. Many other NMSs and in particular hallucinations, cognitive impairment, sleep disorders and difficulty in swallowing strongly affect the advanced stage of disease, and represent a real therapeutic challenge when these symptoms are simultaneously present with different severity. If not adequately treated, they can increase the risk of hospitalization and admissions in nursing home, and profoundly and negatively influence the quality of life and participation in social activity of these patients. PD subtypes according to the combination of motor and non-motor symptoms have been recently proposed. This classification derives from cluster analysis which permits to identify statistically distinct subtypes of Parkinsonian patients according to the relevance of both motor and non-motor symptoms. In this point of view, we propose a schematic therapeutic approach of motor and non-motor symptoms in Parkinson’s disease according to cluster symptoms presentation (motor and non-motor symptoms) and using medications that act on multiple domains of PD symptoms.
Export Options
About this article
Cite this article as:
Lauretani Fulvio, Saginario Antonio, Ceda Paolo Gian, Galuppo Laura, Ruffini Livia, Nardelli Anna and Maggio Marcello, Treatment of the Motor and Non-Motor Symptoms in Parkinson's Disease According to Cluster Symptoms Presentation, Current Drug Targets 2014; 15 (10) . https://dx.doi.org/10.2174/1389450115666140826104030
DOI https://dx.doi.org/10.2174/1389450115666140826104030 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aldosterone and the Pathogenesis of Hypertension
Current Hypertension Reviews Development and Validation of Novel UPLC-MS/MS Method for the Analysis of Macitentan in Pharmaceutical Formulations
Current Pharmaceutical Analysis Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Antenatal Maternal Antidepressants Drugs Affect S100B Concentrations in Fetal-Maternal Biological Fluids
CNS & Neurological Disorders - Drug Targets Obesity-Induced Cerebral Hypoperfusion Derived from Endothelial Dysfunction: One of the Risk Factors for Alzheimer's Disease
Current Alzheimer Research Management of Blood Pressure and Heart Rate in Patients with Acute Stroke
Current Pharmaceutical Design Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma
Current Drug Delivery PPARγ Agonists: Beneficial Effect on Blood Pressure Beyond Glycemic Control?
Current Hypertension Reviews Green Tea Catechins and Cardiovascular Health: An Update
Current Medicinal Chemistry Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Vasopressin Secretion Control: Central Neural Pathways, Neurotransmitters and Effects of Drugs
Current Pharmaceutical Design Gene Expression Profiling as a Tool for Positional Cloning of Genes- Shortcut or the Longest Way Round
Current Genomics Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Oxidized-LDL and Paraoxonase-1 As Biomarkers of Coronary Artery Disease in Patients with Sleep-Disordered Breathing
Current Medicinal Chemistry Editorial (Hot Topic: New Insights into Insulin Resistance, Cardiovascular Diseases and Oxidative Stress: Pathophysiological and Clinical Consequences)
Current Pharmaceutical Design The Roles of MicroRNAs in Heart Diseases: A Novel Important Regulator
Current Medicinal Chemistry